AtriCure, Inc. (ATRC) , a leading innovator in surgical treatments for atrial fibrillation (Afib), has announced regulatory approval for its EnCompass Clamp in CE-marked countries within the European Union.European surgeons have already performed the first series of cases using the device. Initially launched in the United States in 2022, the EnCompass Clamp is designed to streamline heart ablation during open-chest surgeries.The EnCompass Clamp incorporates key features of AtriCure’s Synergy Clamp family, i ...

AtriCure, Inc. (ATRC) recently announced the treatment of the first patient with the AtriClip FLEX-Mini device. The device recently received the FDA 510(k) clearance.The AtriClip FLEX-Mini, the smallest surgical left atrial appendage (LAA) device available, raises the standard with its easy-to-use, simple design that provides physicians with better visibility and access. It builds on the well-proven technology of AtriCure's AtriClip platform.The recent developments regarding AtriCure’s ArtiClip devices are ...

AtriCure, Inc. (ATRC) recently announced the receipt of an expanded indication for the AtriClip in CE-marked countries in Europe. The product is now indicated for use in patients at high risk of thromboembolism for whom left atrial appendage (LAA) exclusion is warranted.The European Commission's expanded indication is based on AtriCure’s clinical findings that patients who are at high risk of thromboembolism can experience fewer strokes with AtriClip.The company expects significant growth potential for the ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $.001 par value ATRC NASDAQ Global Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________________________ FORM 10-Q ___________________________________________________________________________________________ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ¨ ...

AtriCure, Inc. (NASDAQ:ATRC) Q2 2024 Earnings Conference Call July 30, 2024 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Lilia Lozada - JPMorgan John Newman - Canaccord Genuity John McAulay - Stifel Financial Corp. Sam Eiber - BTIG Danielle Antalffy - UBS Daniel Stauder - Citizens JMP Suraj Kalia - Oppenheimer & Co. Joseph Conway - Needham & Company Operator Good a ...

AtriCure (ATRC) reported $116.27 million in revenue for the quarter ended June 2024, representing a year-over-year increase of 15.2%. EPS of -$0.17 for the same period compares to -$0.12 a year ago.The reported revenue represents a surprise of -0.04% over the Zacks Consensus Estimate of $116.32 million. With the consensus EPS estimate being -$0.15, the EPS surprise was -13.33%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Str ...

AtriCure (ATRC) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -13.33%. A quarter ago, it was expected that this medical device maker would post a loss of $0.21 per share when it actually produced a loss of $0.25, delivering a surprise of -19.05%.Over the last four quarters, the company has ...

Exhibit 99.1 For immediate release July 30, 2024 AtriCure Reports Second Quarter 2024 Financial Results • Worldwide revenue of $116.3 million – an increase of 15.2% year over year • Positive cash flow generation of $8.1 million in second quarter 2024 MASON, Ohio, July 30, 2024 – AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2024 f ...

Company Overview - AtriCure, Inc. has received regulatory approval from China's National Medical Products Administration (NMPA) for its AtriClip Left Atrial Appendage (LAA) Exclusion System, allowing the company to market and sell several models of the AtriClip device in China, thereby expanding access to its cardiac solutions [1] - The AtriClip device is designed to exclude and electrically isolate the left atrial appendage during cardiac surgery, which is crucial for managing atrial fibrillation (Afib) and reducing related complications [1][2] Significance of the Approval - The approval is a significant advancement in providing effective treatments for Afib patients in China, as the left atrial appendage is the primary source of blood clots in these patients [2] - The AtriClip device has been used in over 550,000 procedures worldwide, highlighting its efficacy and unique design [2] - AtriCure plans to collaborate with top medical institutions in China to ensure comprehensive training and support, maintaining high standards of patient care [2] Industry Prospects - The global left atrial appendage closure devices market was valued at $1.6 billion in 2023 and is expected to reach $5.3 billion by 2032, growing at a CAGR of 14.1% [3] - Growth drivers include the increasing prevalence of atrial fibrillation, a strong product pipeline, and government initiatives, supported by a robust healthcare system and specialized cardiac centers [3] Recent Developments - In April, AtriCure introduced the cryoSPHERE+ cryoablation probe, which features advanced insulation technology that decreases freeze times by 25% compared to the previous model [4] - The cryoSPHERE+ is currently in an extended limited launch in the United States, with a full release anticipated by the end of the second quarter [4] Price Performance - AtriCure's shares have declined by 30.8% so far this year, contrasting with a 4.1% rise in the industry and a 17% rise in the S&P 500 during the same period [5]

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $.001 par value ATRC NASDAQ Global Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________________________ FORM 10-Q ___________________________________________________________________________________________ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ¨ ...